Hepion investor Rickel reports 5.7% stake

Kenneth Rickel reports a 5.7% beneficial stake in Hepion Pharmaceuticals, Inc. (HEPA), including shares underlying warrants.

Rhea-AI Filing Summary

Hepion Pharmaceuticals, Inc. (HEPA) received a Schedule 13G reporting that investor Kenneth Rickel beneficially owns 5,250,000 shares of its common stock, representing 5.7% of the outstanding shares. This total includes 2,000,000 shares issuable upon exercise of warrants.

As of August 10, 2026, Hepion had 90,219,317 shares of common stock outstanding, which is used as the denominator in calculating this ownership percentage. Rickel is reported to have sole voting power and sole dispositive power over all 5,250,000 shares and no shared voting or dispositive power.

Key Figures

Beneficial ownership: 5,250,000 shares Ownership percentage: 5.7% Shares underlying warrants: 2,000,000 shares +3 more

6 metrics

Beneficial ownership 5,250,000 shares Shares of Hepion Pharmaceuticals, Inc. common stock beneficially owned by Kenneth Rickel

Ownership percentage 5.7% Percent of Hepion common stock class beneficially owned by Kenneth Rickel

Shares underlying warrants 2,000,000 shares Common shares issuable upon exercise of warrants included in beneficial ownership

Shares outstanding 90,219,317 shares Hepion common stock outstanding as of August 10, 2026, used as denominator

Sole voting power 5,250,000 shares Shares over which Kenneth Rickel has sole power to vote or direct the vote

Sole dispositive power 5,250,000 shares Shares over which Kenneth Rickel has sole power to dispose or direct disposition

Key Terms

beneficially owned, sole voting power, sole dispositive power

3 terms

beneficially owned financial

"5,250,000 shares beneficially owned by the reporting person including 2,000,000 shares"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole voting power financial

"Sole Voting Power 5,250,000.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

sole dispositive power financial

"Sole Dispositive Power 5,250,000.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What ownership stake in HEPA does Kenneth Rickel report on this Schedule 13G?

Kenneth Rickel reports beneficial ownership of 5,250,000 shares of Hepion Pharmaceuticals, Inc. common stock, representing 5.7% of the class, using 90,219,317 shares outstanding as of August 10, 2026 as the calculation base.

How much of Hepion Pharmaceuticals, Inc. (HEPA) stock can Kenneth Rickel vote?

Kenneth Rickel is reported to have sole voting power over 5,250,000 shares of Hepion Pharmaceuticals, Inc. common stock and no shared voting power over any shares.

Does Kenneth Rickel’s HEPA position include warrants?

Yes. The 5,250,000 shares beneficially owned by Kenneth Rickel include 2,000,000 shares of Hepion common stock that are issuable upon exercise of warrants, in addition to already outstanding shares.

What share count for HEPA is used to calculate the 5.7% ownership?

The 5.7% ownership is calculated using a denominator of 90,219,317 shares of Hepion Pharmaceuticals, Inc. common stock outstanding as of August 10, 2026.

What dispositive power over HEPA shares does Kenneth Rickel report?

Kenneth Rickel reports sole dispositive power over 5,250,000 shares of Hepion common stock and no shared dispositive power, meaning he alone can decide whether and how to dispose of those shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 05:30 PM Accepted by SEC EDGAR 09/15/2026 - 05:30 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Hepion Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

426897401

(CUSIP Number)

08/03/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 426897401

1

Names of Reporting Persons

Kenneth Rickel

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 5,250,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 5,250,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,250,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.7 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: The percentage reported in row 13 above is calculated with a numerator of 5,250,000 shares beneficially owned by the reporting person including 2,000,000 shares of common stock issuable upon exercise of warrants and a denominator of 90,219,317 shares of Common Stock outstanding as of August 10, 2026.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Hepion Pharmaceuticals, Inc.
(b)	Address of issuer's principal executive offices: 34 Shrewsbury Ave., Suite 1D, Red Bank, NEW JERSEY, 07701
Item 2.
(a)	Name of person filing: Kenneth Rickel
(b)	Address or principal business office or, if none, residence: c/o Hepion Pharmaceuticals, Inc., 34 Shrewsbury Ave., Suite 1D, Red Bank, NEW JERSEY, 0770
(c)	Citizenship: United States
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP Number(s): 426897401
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 5,250,000
(b)	Percent of class: 5.7%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 5,250,000
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 5,250,000
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Kenneth Rickel

Signature:	/s/ Kenneth Rickel
Name/Title:	Kenneth Rickel
Date:	09/15/2026